Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery
Journal of Clinical Medicine · 17.11.2026 · 15 (22) · 9014
DOI: 10.3390/jcm15229014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.11.2026. Verfasst von Guido Stirnimann und 8 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Direct oral anticoagulants (DOAC) are widely used for the prevention and treatment of venous thromboembolism (VTE) in the general population. However, evidence on their efficacy and safety in patients undergoing bariatric surgery remains limited. The objective of this study was to investigate the effect of bariatric surgery on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of therapeutic-dose rivaroxaban.
Methods
This single-centre clinical study retrospectively analysed PK/PD data from patients with a body mass index (BMI) ≥ 35 kg/m2 receiving extended anticoagulation with 20 mg rivaroxaban. Rivaroxaban PK (plasma concentrations) and PD (prothrombin fragments F1 + 2 and D-dimers) parameters were repeatedly measured prior to and up to 3 months after bariatric surgery.
Results
Nine patients (mean age 50 years, 78% female) with a mean BMI of 46.8 kg/m2 were included; seven patients underwent sleeve gastrectomy and two underwent Roux-en-Y gastric bypass surgery. The geometric mean rivaroxaban areas under the curve (AUC) before, and at 3 days, 30 days, and 3 months after bariatric surgery were 2441.8 µg·h/L (geometric coefficient of variation (GCV) 1.44, n = 7), 2474.7 µg·h/L (GCV 1.41, n = 9), 2468.2 µg·h/L (GCV 1.74, n = 8), and 3266.4 µg·h/L (GCV 1.25, n = 6), respectively. Prothrombin fragments F1+2 showed a time-dependent decrease after rivaroxaban administration during the early postoperative period, comparable to that observed in the presurgical measurements. Mean D-dimer levels were increased immediately after bariatric surgery (consistent with a surgery-related increase), but were comparable to the presurgical measurement at later time points.
Conclusions
Based on the limited PK/PD data, rivaroxaban exposure, as assessed by AUC, remained comparable to presurgical values during the first three months after bariatric surgery. These findings are exploratory and require confirmation in larger prospective studies.
Zitieren
APA
Stirnimann, G., Clerc, Y., Nett, P. C., Borbély, Y. M., Fischer, J., Schädelin, S., Calderara, D. B., Alberio, L., & Kröll, D. (2026). Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery. Journal of Clinical Medicine, 15(22), 9014. https://doi.org/10.3390/jcm15229014
Vancouver
Stirnimann G, Clerc Y, Nett PC, Borbély YM, Fischer J, Schädelin S, et al. Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery. Journal of Clinical Medicine. 2026;15(22):9014. doi:10.3390/jcm15229014
BibTeX
@article{Stirnimann2026,
author = {Stirnimann, Guido and Clerc, Yannic and Nett, Philipp C. and Borbély, Yves Michael and Fischer, Jonas and Schädelin, Sabine and Calderara, Debora Bertaggia and Alberio, Lorenzo and Kröll, Dino},
title = {Pharmacokinetics and Pharmacodynamics of Therapeutic-Dose Rivaroxaban Prior to and Early After Bariatric Surgery},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {22},
pages = {9014},
doi = {10.3390/jcm15229014}
}
EUVIMED